%20LIMITED%2010-Dec-2007_files/image002.jpg){kind=small}
MIRA
INFORM REPORT
|
Report Date : |
10.12.2007 |
IDENTIFICATION
DETAILS
|
Name : |
BOSCH PHARMACEUTICALS (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
Plot # 221, Sector 23,
Korangi Industrial Area, Karachi, |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Date of Incorporation : |
1992 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of
Pharmaceutical Products |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
COMPANY NAME
BOSCH PHARMACEUTICALS (PRIVATE) LIMITED
Address
Registered Address & Factory
Plot # 221, Sector
23, Korangi Industrial Area, Karachi, Pakistan
Tel 92 (21) 5053103
Fax 92 (21) 5053104
Email marketing@bosch-pharma.com
Short Description Of
Business
Nature of Business Manufacture & Marketing of Pharmaceutical Products
Year Established 1992
Registration # 0027160
Head Office
Address 8, Modern Society, Tipu Sultan
Road, Karachi, Pakistan
Tel # 92 (21) 4541876, 4541878,
4543618, 4543641
Fax # 92 (21) 4545915
Auditors
M/s F. Ahmad & Co.
(Chartered Accountants)
10/4, Bank House No. 1, Habib Square, M.A.
Jinnah Road, Karachi, Pakistan
Legal Status
Subject Company was established as a Private
Limited Company in 1992
Shares
AUTHORIZED
CAPITAL Rs. 100,000,000/-
divided into 1,000,000 shares of Rs. 100/- each
ISSUED
& PAID UP CAPITAL Rs. 80,000,000/-
divided into 800,000 shares of Rs. 100/- each
Details of Directors
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. S. Mohiuddin Chawla Mr. Zakaria Nasib Mr. Farhan Chawla Mr. Ahmed Nasib |
Pakistani Pakistani Pakistani Pakistani |
43/30, Block No. 7 & 8, Overseas Co-operative Housing Society,
Karachi 43/30, Block No. 7 & 8, Overseas Co-operative Housing
Society, Karachi 38-O, Block 6, P.E.C.H.S., Karachi 43/30, Block No. 7 & 8, Overseas Co-operative Housing
Society, Karachi |
Business Business Business Business |
Chief Executive Director Director Director |
Shareholders
|
Names |
No. of Shares |
|
Mr. S. Mohiuddin Chawla Mr. Zakaria Nasib Mr. Farhan Chawla Mr. Ahmed Nasib |
203,750 199,700 196,250 200,300 |
Associates
SUBSIDIARY
None
ASSOCIATED COMPANIES
Pakistan International Packages (Pvt.) Ltd, Pakistan.
Munico Associates International, Pakistan.
(3) Linz Pharmaceuticals (Pvt) Limited, Pakistan.
Products
Manufacture & marketing of different pharmaceutical class like Anti
Biotic, Anti Malarials, Anti-Rheumatic, Antihistamine, Narcotic Analgesic, Non
Steroidal Respiratory Anti Inflamatory, Quinolones, Vitamins, Phenothiazine,
Hypolipidaemics, Muscle Relaxant with their brand names of ALOC, AMKAY, AMPIN,
AMPLUS, ATLIN, BEASY, BOSCHOCLOX, BOSCHOFEN, BOSCHTAMOL, BOSCHTAN, BOSCHTRIM,
BTROL, CALAMOX, CALOC, CEBAC, CEBOSH, CEFALOR, CEFAZOL, CEFOTAX, CEFRINEX,
CEFXONE, CEPRAZONE, CHLORAMPHENICOL, CORACE, DEXAMEX, DOLO-K, DROMAX, DURIDE,
FORTAZIM, GENTIC, GLAX, IVCEF, LOREFECT, MALADRIN, NOROCIN, NULCER, NUZIB,
ODENIL, OGREL, OLINC, OMEZOL, ORTHOFENAC, ORVA, OSTEON, PEPTILOC, PRELOX,
PROTOZOL, QUINOFLOX, QUMIC, SAISTA, SOMEZOL, SUPRAMOX, TANZO, TARIFLOX FORTE,
TEZOX, ULCELOC, VARIBA, ZECEF, ZEZOT
Number of Employees
275
Annual Production
Volume
The capacity and production of the company’s
plant is indeterminable as it is multi-product and involves varying processes
of manufacturing.
Annual Sales Volume
Year In
Pak Rupees
2006 250,000,000/- (Estimated)
Trade Suppliers
(Foreign)
AUROBINDO PHARMA, INDIA.
AURINDO PHARMA, INDIA.
INOGENT LABORATORIES (PVT) LIMITED, INDIA.
Distributors
Mainly in all
major cities of Pakistan
Exporting Countries
Mainly to Afghanistan & African
Countries
Bankers
United Bank Limited, State
Life Building 1, I.I. Chundrigar Road, Karachi, Pakistan
(2) United Bank Limited, Shaheed-e-Millat Branch,
Shaheed-e-Millat Road, Karachi, Pakistan.
Memberships
Pakistan Pharmaceutical Manufacturers Associations.(PPMA)
Karachi Chamber of Commerce & Industry.(KCCI)
Foreign Exchange
Rates
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 61.45 |
|
UK Pound |
1 |
Rs. 124.40 |
|
Euro |
1 |
Rs. 89.70 |
Comments
Subject Company was established in 1992 and is engaged in manufacturing
& marketing of Pharmaceutical Products. Market reputation is good. Trade relations
are reported as fair. The Company can be considered for normal business
dealings at usual trade terms and conditions.
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)